Introduction {#s1}
============

India has the maximum burden of tuberculosis (TB) in the world. World Health Organization (WHO) estimated 8.7 million incident cases and 12 million prevalent cases worldwide in 2011. India and China accounted for almost 40% of the world's TB cases. Globally, there were an estimated 630 000 cases of MDR-TB (range, 460 000--790 000) among the world's 12 million prevalent cases of TB in 2011. Worldwide, 3.7% of new cases and 20% of previously treated cases were estimated to have MDR-TB. India, China, the Russian Federation and South Africa have almost 60% of the world's cases of MDR-TB [@pone.0055299-World1].

Globally, emergence of drug resistance is a dangerous alarm. The increase in the incidence of MDR-TB and the emergence of XDR-TB presents tremendous challenges to the global efforts to battle tuberculosis. MDR-TB, defined as resistance to both INH and RIF, is difficult to cure and requires prolonged treatment with expensive and often toxic multidrug regimens. XDR-TB is defined as resistance to at least INH and RIF (MDR-TB) with additional resistance to any fluoroquinolone and at least one of three injectable anti-TB drugs (AMK, CAP or Kanamycin (KAN) [@pone.0055299-Migliori1]--[@pone.0055299-Centers1], and is known to emerge from MDR-TB, with the acquisition of further drug resistance mutations. Recently published studies and a systematic review have shown that XDR-TB is associated with higher probability of failure and death, and lower probability of treatment success than MDR-TB [@pone.0055299-Migliori1].

Rapid methods enabling accurate susceptibility testing of first-line and second-line drugs are critical for the early diagnosis of MDR-TB and XDR-TB and the initiation of effective regimens [@pone.0055299-GraceLin1]--[@pone.0055299-Martin1]. We report the detection of XDR-TB from statistically significant number of MDR suspects (by 5% level of significance) from Delhi. We screened 611 MDR suspects from 2007 to 2010 and identified isolates meeting the criteria for MDR and XDR-TB [@pone.0055299-World2]. This study points to the existence of XDR-TB in Delhi, India and highlights the lacunae of delayed diagnosis of drug resistance under the program conditions as many of the XDR-TB patients would have initially had MDR-TB that slowly progressed to XDR-TB.

Materials and Methods {#s2}
=====================

Sample Size Calculation {#s2a}
-----------------------

Some previous reports from India have shown that close to 5% of the MDR-TB strains are XDR-TB [@pone.0055299-Mondal1]--[@pone.0055299-Balaji1]. Assuming that the prevalence of XDR-TB patients among MDR-TB patients is 5% and it varies from 2%--8%. Considering 5% alpha error (ά) and permissible error (d) as 2%, we had to enroll at least 475 MDR-TB patients. The sample size was calculated by using the standard formula.

Where Z^2^ ~1−α/2~ is the standard normal deviate at α level of significance (1.96), p is the prevalence of particular group; q = 1−p; d is permissible error at 5% level of significance.

Ethics Statement {#s2b}
----------------

This study was approved by the institutional ethics review committee, (IEC approval no. T-10/31.10.2008) AIIMS, New Delhi. Written informed consent was obtained from each patient prior to collection of sputum sample.

Collection of Clinical Isolates of *M. tuberculosis* {#s2c}
----------------------------------------------------

A total of 611 patients were enrolled and sputum samples collected from four different tertiary care hospitals treating TB in Delhi. All patients were enrolled on the basis of inclusion criteria (Cases clinically suspected to be suffering from drug resistant tuberculosis/category I or category II failure cases). Patient information was collected in a standard proforma. Demographic data was collected viz. gender, age, address, employment, economic status, literacy, living conditions, household contacts, professional work contacts, chest radiological findings, any other associated illness and HIV infection.

*M. tuberculosis* Culture and Drug Susceptibility Testing by MGIT 960 {#s2d}
---------------------------------------------------------------------

All samples were processed using NALC-NaOH method [@pone.0055299-Kent1] and smears were examined after Ziehl--Neelsen staining. Processed samples were inoculated into MGIT 960 non-radiometric automated isolation system (Becton Dickinson, Sparks, MD, USA). MGIT tube was supplemented with 0.8 ml of Oleic Acid-Albumin-Dextrose-Catalase (OADC) along with mixture of five antibiotics; Polymixin B, Amphotericin B, Nalidixic acid, Trimethoprim, and Azlocillin (PANTA) and 0.5 ml of decontaminated sample. *M. tuberculosis* complex and non-tubercular mycobacteria (NTM) were differentiated using p-nitrobenzoic acid (PNB) test (as per the manufacturer's instructions) [@pone.0055299-Siddiqi1].

The standard protocol for DST of RIF and INH in the MGIT 960 was followed according to the manufacturer's instructions [@pone.0055299-Siddiqi1]. Briefly, to each 7 ml MGIT tube, 0.8 ml of supplement (MGIT 960 SIRE supplement) and 0.1 ml of the drug stock (Becton Dickinson, USA) (final concentrations were 0.1 µg/ml for INH and 1 µg/ml for RIF) solution were aseptically added and finally 0.5 ml of the test inoculum was added. For each isolate, a growth control (GC) with growth supplement but without drug was included. To prepare GC the inoculum was prepared by pipetting 0.1 ml of the test inoculum with 10 ml of sterile saline to make a 1∶100 dilution; 0.5 ml of GC inoculum was added to a drug free MGIT tube. All of the inoculated tubes were placed into MGIT 960 instrument on the same day.

DST for second line drugs was performed on MDR-TB isolates by using 5 µg/ml of ETA, 2.5 µg/ml of CAP, 2 µg/ml of OFX and 1.0 µg/ml of AMK(Sigma-Aldrich, St.Louis, Mo, USA) [@pone.0055299-Rodrigues1]--[@pone.0055299-World3] in MGIT 960. XDR-TB isolates were further tested by 2.5 µg/ml of KAN and 2.0 µg/ml of Levofloxacin (LVF) (Sigma-Aldrich, St. Louis, Mo, USA) [@pone.0055299-Rodrigues1], [@pone.0055299-World3]. All the tubes were tightly recapped and mixed well. All inoculated drug-containing and GC tubes were placed in the DST set carrier and entered into the MGIT 960 instrument as 'unknown drugs' using the AST (antimicrobial susceptibility testing) entry feature.

Case Definition {#s2e}
---------------

MDR-TB was defined as tuberculosis disease caused by a strain of *M. tuberculosis* that was resistant to at least RIF and INH. Pre-XDR was defined as disease caused by a strain resistant to RIF and INH and either a fluoroquinolone or a second-line injectable drug, but not both [@pone.0055299-Banerjee1]. XDR-TB was defined as TB with resistance to at least RIF, INH, a fluoroquinolone and one of three second-line injectable drugs (CAP, AMK Or KAN) [@pone.0055299-World4].

Analysis {#s2f}
--------

The following risk factors were analyzed: gender, age, smoking, alcohol use, socioeconomic status, residence location, co-morbidities, previous treatment history, BCG status, family TB history, previous use of fluoroquinolone or injectable drugs and cavitation on chest X-ray. Data was analyzed using the SPSS software, version 10.0 (SPSS Inc, Chicago, IL, USA). Comparisons of categorical variables were performed using the Pearson Chi-square test to compare different groups. Non-categorical variables (age and socioeconomic status) were analyzed by Kruskal-Wallis test. A p-value of \<0.05 was considered as statistically significant.

Results {#s3}
=======

Characteristics of the Study Population {#s3a}
---------------------------------------

Six hundred eleven patients with clinical suspicion of drug resistant TB (Cat I/II treatment failure cases) were enrolled. DST for RIF and INH on these patients showed 483 to be infected with MDR-TB strains. Of 483 MDR-TB isolates, 18 (3.7%) strains were found to be XDR-TB, 7.5% MDR-TB strains were resistant to OFX alone and 5% MDR-TB strains were resistant to second line injectable drugs (AMK and CAP), termed as pre-XDR ([Fig. 1](#pone-0055299-g001){ref-type="fig"}).

![Diagram shows the distribution of multidrug-resistant/pre-extensively drug-resistant and extensively drug-resistant *M. tuberculosis* isolates with additional resistance profile.](pone.0055299.g001){#pone-0055299-g001}

All XDR-TB (n = 18) isolates were tested for sensitivity to KAN and LVF and had the same resistance pattern as with AMK and OFX ([Table 1](#pone-0055299-t001){ref-type="table"}), with one exception, an isolate sensitive to AMK was found resistant to KAN.

10.1371/journal.pone.0055299.t001

###### Drug resistance pattern of XDR-TB patients.

![](pone.0055299.t001){#pone-0055299-t001-1}

  Strain ID    Drug susceptibility testing (DST)              
  ----------- ----------------------------------- --- --- --- ---
  M 1                          R                   R   R   R   S
  M2                           R                   R   R   R   R
  M 3                          R                   R   R   R   S
  M 4                          R                   R   R   R   R
  M 5                          S                   S   R   R   R
  M 6                          R                   R   R   R   S
  M 7                          R                   R   R   R   R
  M 8                          S                   S   R   R   R
  M 9                          S                   S   R   R   R
  M 10                         S                   S   R   R   R
  M 11                         R                   R   R   R   R
  M 12                         R                   R   R   R   R
  M 13                         R                   R   R   R   S
  M 14                         S                   R   R   R   R
  M 15                         R                   R   R   R   S
  M 16                         R                   R   R   R   S
  M 17                         S                   S   R   R   R
  M 18                         R                   R   R   R   S

Note: R = Resistant, S = Sensitive.

Of 611 enrolled patients, 2 were HIV sero-positive but were culture negative for *M.tb* and hence were excluded from the study.

Among MDR-TB patients, 36.8% patients were females with the mean age of 31 years (SD 11.2). Fifty percent of MDR patients showed cavitation on Chest X-ray (CXR) and 62% patients had previously taken either 2^nd^ line injectables or fluoroquinolones ([Tables 2](#pone-0055299-t002){ref-type="table"}, [3](#pone-0055299-t003){ref-type="table"} and [4](#pone-0055299-t004){ref-type="table"}).

10.1371/journal.pone.0055299.t002

###### Comparison of clinical characteristics (categorical values) of MDR, p-XDR and XDR-TB isolates.

![](pone.0055299.t002){#pone-0055299-t002-2}

  Characteristics                                        MDR-TB total number (%)   p-XDR-TB total number (%)   XDR-TB total number (%)    p value   
  ----------------------------------------------------- ------------------------- --------------------------- ------------------------- ----------- -----------
  Sex                                                             Male                    260 (63.1)                  25 (47.2)          12 (66.6)     0.072
                                                                 female                   152 (36.9)                  28 (52.8)          6 (33.3)      0.072
  Previous TB treatment (n = 483)                                  Yes                    380 (92.2)                  51 (96.2)          17 (94.4)     0.551
                                                                   No                      32 (7.8)                    2 (3.8)            1 (5.5)      0.551
  Family TB history (n = 483)                                      Yes                     72 (17.5)                  11 (20.7)          7 (38.9)    **0.045**
                                                                   No                     340 (82.5)                  42 (79.2)          11 (61.1)   **0.045**
  Smoker (n = 483)                                                 Yes                    168 (40.8)                  20 (37.7)          9 (50.0)      0.658
                                                                   No                     244 (59.2)                  33 (62.2)          9 (50.0)      0.658
  Alcohol (n = 483)                                                Yes                    125 (30.3)                  14 (26.4)          7 (38.9)      0.604
                                                                   No                     287 (69.7)                  39 (73.6)          11 (61.)      0.604
  Residence (n = 483)                                             Urban                   194 (47.0)                  23 (43.0)          5 (27.7)      0.612
                                                                  Rural                   218 (52.0)                  30 (56.0)          13 (72.0)  
  Co-morbidity (n = 254)                                           Yes                     19 (4.61)                   4 (7.5)           6 (33.3)    **0.001**
                                                                   No                     393 (95.4)                  49 (92.4)          12(66.6)    **0.001**
  CXR cavitation (n = 254)                                         Yes                    107 (51.7 )                 17 (56.6)          10 (58.8)     0.767
                                                                   No                     100 (48.3)                  13 (43.3)          7 (41.9)      0.767
  BCG status (n = 163)                                             Yes                     59 (47.5)                  12 (52.2)          5 (31.2)      0.397
                                                                   No                      65 (52.4)                  11 (47.8)          11 (68.7)     0.397
  Category status                                                                                                                                   
  CATI failed                                                                             154 (37.4)                  21 (39.6)          5 (27.8)      0.74
  CATII failed                                                                            209 (50.7)                  28 (52.8)          4 (22.9)      0.66
  CATIV failed                                                                             18 (4.4)                    1 (1.8)           7 (38.9)    **0.049**
  Not known                                                                                31 (7.5)                    3 (5.7)           2 (11.1)   
  Previously taken FQs(n = 93/163)                                 Yes                     68 (54.8)                  15 (65.2)          10 (62.5)     0.586
                                                                   No                      56 (45.8)                  8 (34.7)           6 (37.5)      0.586
  Previously taken 2^nd^ line injectable (n = 22/163)              Yes                      9 (7.2)                   3 (13.0)           10 (62.5)   **0.001**
                                                                   No                     115 (92.7)                  20 (86.9)          6 (37.5)    **0.001**

P values were calculated using chi-square test, values \<0.05 considerd as significant.

CXR = Chest X-Ray, MDR-TB = Multi Drug Resistant Tuberculosis, p-XDR-TB = Pre Extensively Drug Resistant Tuberculosis, XDR-TB = Extensively Drug Resistant Tuberculosis, FQS = Fluroquinolones, BCG =  Bacillus Calmette--Guérin.

**Boldface** indicates statistically significant differences.

10.1371/journal.pone.0055299.t003

###### P value comparison of patients with history of previous intake of 2^nd^ line injectable drugs among MDR, p-XDR and XDR-TB isolates.

![](pone.0055299.t003){#pone-0055299-t003-3}

  Patients with history of previous intake of 2^nd^ line injectables (n = 22/163)   
  --------------------------------------------------------------------------------- -----------
  MDR vs. p-XDR                                                                        0.352
  MDR vs. XDR                                                                        **0.000**
  p-XDR vs. XDR                                                                      **0.001**

P values were calculated using Fisher\'s exact test, values \<0.05 considerd as significant.

MDR-TB = Multi Drug Resistant Tuberculosis, p-XDR-TB = Pre Extensively Drug Resistant Tuberculosis, XDR-TB = Extensively Drug Resistant Tuberculosis.

**Boldface** indicates statistically significant differences.

10.1371/journal.pone.0055299.t004

###### Comparison of clinical characteristics (non-categorical values) of MDR, p-XDR and XDR-TB isolates.

![](pone.0055299.t004){#pone-0055299-t004-4}

                                 Mean±Standard Deviation                                        
  ----------------------------- ------------------------- ------------------- ----------------- -----------
  Age                                31.7**±**11.27          32**±**12.81       34.4**±**8.9       0.469
  Previous TB history (years)         0.97**±**0.15          0.98**±**0.13      0.94**±**0.23      0.677
  INR                               5840.5**±**8494.5      5020.7**±**6179.2   8000**±**9639.0   **0.013**

P values were calculated using Kruskal-Wallis test, values\<0.05 considerd as significant.

MDR-TB = Multi Drug Resistant Tuberculosis, p-XDR-TB = Pre Extensively Drug Resistant Tuberculosis, XDR-TB = Extensively Drug Resistant Tuberculosis, INR = Indian National Rupees.

**Boldface** indicates statistically significant differences.

Among pre-XDR-TB patients (n = 53), 52.8% were females with the mean age of 32 years (SD 12). Fifty six percent of these patients showed cavitation on CXR and 78% patients had a history of taking either fluoroquinolones or one of the 2^nd^ line injectable drugs. Twenty percent patients gave a family history of TB ([Tables 2](#pone-0055299-t002){ref-type="table"}, [3](#pone-0055299-t003){ref-type="table"} and [4](#pone-0055299-t004){ref-type="table"}).

In XDR-TB cases, 33.3% patients were females and the mean age was 34 years (SD 8.9). Seven patients had co-morbidities (*i.e.* diabetes mellitus, myasthenia gravis and thalassemia intermedia) and 38.8% patients gave a history of tuberculosis in their families. Fifty eight percent patients had cavitation on CXR and 81% patients had previously taken either fluoroquinolones or 2^nd^ line injectables ([Tables 2](#pone-0055299-t002){ref-type="table"}, [3](#pone-0055299-t003){ref-type="table"}, [4](#pone-0055299-t004){ref-type="table"} and [5](#pone-0055299-t005){ref-type="table"}).

10.1371/journal.pone.0055299.t005

###### Treatment history of XDR *M. tuberculosis* isolates.

![](pone.0055299.t005){#pone-0055299-t005-5}

  Strain ID    Previous treatment for TB/Previous pattern of drug resistance   [\*](#nt112){ref-type="table-fn"}Name of Drugs   [\*\*](#nt113){ref-type="table-fn"}Treatment after DST report        Co-morbidities        Family history/Death    Outcome
  ----------- --------------------------------------------------------------- ------------------------------------------------ --------------------------------------------------------------- -------------------------- ---------------------- -----------
  M 1                                   Yes/MDR-TB                                         KAN, ETA, D-CS,PZA, AX                          CAP, CFZ, CLARI, MOX, PAS,High Dose INH                 Diabetes mellitus                NH               NA
  M2                                    Yes/MDR-TB                                          D-CS, ETA, PAS, LVF                          CFZ, CLARI, MOX, PAS, Amoxiclav, Linezolid                       None                  Mother/No         Defaulter
  M 3                        Yes/TB, DST (2^nd^ line) ongoing                                       HRZE                             CAP, CFZ, CLARI, MOX, PAS, Linezolid, High dose INH                  None                      NH             Expired
  M 4                                   Yes/MDR-TB                                           ETH, ETA, D-CS,OFX                   CFZ, CLARI, MOX, PAS, Amoxiclav, Linezolid,High dose INH         Myasthenia gravis       Father & brother/Yes    Expired
  M 5                        Yes/TB, DST (2^nd^ line) ongoing                                   CAT II DOTS                         CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH         Thalassemia intermedia             NH             Expired
  M 6                                   Yes/MDR-TB                                           KAN,ETA, D-CS,PZA                              CAP, CFZ, CLARI, MOX, PAS, Linezolid                          None                      NH               NA
  M 7                                   Yes/MDR-TB                                          KAN,ETA,ETZ,PAS,PZA                     CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH                  None                  Husband/No        Defaulter
  M 8                                   Yes/MDR-TB                                     KAN, PAS, PZA, ETA, LVF, D-CS                CLARI, CFZ, MOX, Amoxiclav, Linezolid, High dose INH                  None                 Brother/Yes        Defaulter
  M 9                        Yes/TB, DST (2^nd^ line) ongoing                                   CAT II DOTS                         CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH           Diabetes mellitus             Uncle/No         Defaulter
  M 10                       Yes/TB, DST (2^nd^ line) ongoing                                   CAT II DOTS                         CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH           Diabetes mellitus                NH             Expired
  M 11                                  Yes/MDR-TB                                          ETA, PAS, PZA, D-CS                   CFZ, CLARI, MOX, PAS, Amoxiclav, Linezolid,High dose INH                None                      NH              Cured
  M 12                       Yes/TB, DST (2^nd^ line) ongoing                                    CATII DOTS                         CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH           Diabetes mellitus                NH               NA
  M 13                                  Yes/MDR-TB                                          KAN, ETA,D-CS,PZA,AX                  CFZ, CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH               None                      NH               NA
  M 14                       Yes/TB, DST (2^nd^ line) ongoing                                    No record                              CFZ, CLARI, MOX, PAS,Linezolid, High dose INH                     None                      NH               NA
  M 15                                  Yes/MDR-TB                                      CAP, CFZ, ETA, D-CS, PZA, AX                             CAP, CFZ, CLARI, MOX, PAS,                               None                      NH               NA
  M 16                       Yes/TB, DST (2^nd^ line) ongoing                                   CAT II DOTS                         CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH                  None                      NH               NA
  M 17                       Yes/TB, DST (2^nd^ line) ongoing                                   CAT II DOTS                         CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH          Spinal tuberculosis           Mother/No            NA
  M 18                       Yes/TB, DST (2^nd^ line) ongoing                                       HRZE                            CLARI, MOX, PAS, Amoxiclav, Linezolid, High dose INH        Transfusion and jaundice            NH               NA

**Note:** All isolates were pulmonary TB patients.

The patients were on treatment with enlisted drugs at the time of sample collection.

The patients were on treatment with enlisted drugs after providing DST report.

MDR-TB = Multi Drug Resistant Tuberculosis, KM = Kanamycin, PZA = Pyrazinamide, ETA = Ethionamide, PAS = Para Amino salicylic acid, LVF = Levofloxacin, D-CS = D-cycloserine, AX = Amoxicillin, ETH = Ethambutol, CAP = Capreomycin, CFZ = Clofazimine, CLARI = Clarithromycin, MOX = Moxifloxacin, INH = Isoniazid, NA = not available, NH = No history.

Risk Factors Associated with Progression of the Disease {#s3b}
-------------------------------------------------------

Extent of cavitations in chest X-ray seemed to be associated with drug resistance, highest cavitations being associated with XDR-TB (though p value was not statistically significant). Past history of fluoroquinolone intake (though not statistically significant) was also associated with p-XDR/XDR-TB ([Tables 2](#pone-0055299-t002){ref-type="table"} and [3](#pone-0055299-t003){ref-type="table"}). Four factors showed significant association with worsening drug resistance, family history of TB (p 0.045), socioeconomic status (p 0.013), co-morbidities (0.001) and previous intake of second line injectable drugs (p 0.001) ([Tables 2](#pone-0055299-t002){ref-type="table"}, [3](#pone-0055299-t003){ref-type="table"} and [4](#pone-0055299-t004){ref-type="table"}). Rural residence seemed to foster XDR-TB while on the contrary there was more MDR-TB and less XDR-TB in urban areas. [Figure 2](#pone-0055299-g002){ref-type="fig"} & [3](#pone-0055299-g003){ref-type="fig"} shows the precise differentiation of these variables among MDR/p-XDR/XDR-TB isolates.

![Line diagram shows the correlation of family TB history, co -morbidity, chest X-ray (CXR) findings and patients who have previously taken OFX OR 2^nd^ line injectables among MDR, p-XDR and XDR *M. tuberculosis* isolates.\
Of these, co-morbidity (p 0.001), family TB history (p 0.045) and previous intake of 2^nd^ line injectable drugs (p 0.001) were significantly associated with progression of the disease. Other two factors (CXR and previously taken OFX) were associated though not significantly.](pone.0055299.g002){#pone-0055299-g002}

![Line diagram shows the correlation of residence (rural and urban) among MDR, p-XDR and XDR *M. tuberculosis* isolates, although the p value was not statistically significant.](pone.0055299.g003){#pone-0055299-g003}

Discussion {#s4}
==========

XDR-TB is a serious global health threat. The emergence of XDR TB reflects a failure to implement the measures recommended in the WHO's Stop TB strategy. This strategy emphasizes expanding high quality DOTS programme [@pone.0055299-Raviglione1].

Emergence of XDR-TB is reported worldwide. Reported prevalence rates of XDR-TB of total MDR cases are: 6.6% overall worldwide, 6.5% in industrialized countries, 13.6% in Russia and Eastern Europe, 1.5% in Asia, 0.6% in Africa and Middle East and 15.4% in Republic of Korea [@pone.0055299-Jain1]. XDR-TB has been reported from 84 countries by end of 2011; the average proportion of MDR-TB cases with XDR-TB is 9.0% and is significantly associated with worse outcome than MDR-TB [@pone.0055299-World1], [@pone.0055299-World2].

The actual incidence and prevalence rate of XDR-TB in India is not available. A few scattered reports: Mondal *et al* reported 7.4% of MDR strains as XDR [@pone.0055299-Mondal1]; a study from Hinduja Hospital, Mumbai revealed 11% of MDR strains as XDR [@pone.0055299-Ajbani1]. Singh *et al* reported 33.3% of MDR TB cases as XDR-TB in a population of HIV sero-positive patients from AIIMS, New Delhi [@pone.0055299-Singh1]. Sharma *et al* found 2.4% of MDR as XDR-TB cases from Delhi [@pone.0055299-Sharma1]. A study conducted by Paramasivan *et al* reported 4.6% XDR-TB cases in Chennai [@pone.0055299-Paramasivan1] and another recent study by Khanna *et al* from Delhi reported 5.76% XDR-TB [@pone.0055299-Khanna1]. None of these studies were carried out as per statistical significance considerations of the numbers of MDR TB isolates included.

Development of drug resistance (MDR/p-XDR/XDR) may result due to various reasons: inappropriate treatment regimens (*i.e*. drug selection, duration of treatment and the correct dosage); patient factors (*i.e.* mal-absorption, poor adherence); programme-related factors (*i.e.*, incompetent health personnel, irregular drug supply). In fact, it has been said that the emergence of MDR-TB is evidence of systematic failure of the global community to tackle a curable disease [@pone.0055299-Singh2].

We designed a cross sectional study and enrolled 611 clinically suspected drug resistant TB patients. Of 611 patients, samples from 483 grew MDR-TB cultures, and eighteen of the 483 MDR-TB isolates were XDR-TB (3.7%). The current study was only designed to study the existence of XDR-TB and the association of risk factors, and not to comment on the prevalence of XDR-TB in India.

Analysis of XDR-TB cases showed that XDR-TB was more frequent among patients with family history of TB (p 0.045) ([Table 2](#pone-0055299-t002){ref-type="table"}). In 33.3% (6/18) of the families of XDR-TB patients, history of TB was recorded, though no information regarding the treatment regimen followed or drug resistance pattern was available. Of these 6 XDR-TB patients, 1 patient expired while 4 were defaulters. The data implies that family contact with TB patients may be one of the main reasons for the spread of the disease. Disease in the family may indicate the role of some genetic or immunological predisposition in families or just the increased transmission due to close and prolonged exposure. Family history of TB could lead to some patients actually getting primary XDR-TB, which may be responsible for florid disease. In addition, compromised care due to social factors such as possible callousness to a challenge that has caused protracted morbidity but no mortality, or loss of faith in the treatment regimens possibly explain the high defaulter rate.

A salient and novel observation in the study was co-morbidities in seven XDR-TB patients. These patients had Diabetes mellitus (n = 4), Myasthenia gravis (n = 1), Thalassemia intermedia (n = 1) and transfusion associated jaundice (n = 1) ([Table 5](#pone-0055299-t005){ref-type="table"}). Patients with an associated pathology showed a higher tendency for acquiring resistance (p 0.001) ([Table 2](#pone-0055299-t002){ref-type="table"}). Patients with co-morbidities often have compromised immunity. Hence we propose a strong role of immune competence in controlling the disease, with or without treatment. A poor immune response would enhance chronicity of disease, and would hence foster accumulation of further mutations and the subsequent selection of a highly resistant clone of bacteria.

It was observed that 83.3% (15/18) of XDR-TB patients were from poor socio-economic status (monthly income, Indian National rupees (INR) \<8,000/-) (p 0.013) ([Table 4](#pone-0055299-t004){ref-type="table"}) due to which these patients may not find it affordable to get the necessary tests done, like DST (not part of programmatic services at the time of the study). Other social factors such as poor nutrition, poor standards of living, hence higher exposure to disease, which come with poor socio-economic status may also contribute. Thus we may infer from the study that socio-economic status may be a contributor for developing drug resistant TB.

Interestingly, patients who had taken 2^nd^ line injectable treatment earlier had higher chances of getting XDR-TB (p 0.001) ([Tables 2](#pone-0055299-t002){ref-type="table"} and [3](#pone-0055299-t003){ref-type="table"}). Jeon *et al* have reported XDR-TB to be associated with the cumulative duration of previous treatment with second-line TB drugs among subjects in a tertiary care TB hospital in S. Korea [@pone.0055299-Jeon1]. Dalton *et al* have reported that prior use of second-line anti-TB drugs more than quadrupled the risk of extremely drug- resistant tuberculosis (XDR-TB) in an 8-country prospective study [@pone.0055299-Dalton1]. Chan *et al* have demonstrated in a cohort of 174 patients with multidrug- resistant TB that 12 patients with multidrug- resistant TB strains resistant to the fluoroquinolones and streptomycin had significantly better initial and long-term outcomes, compared with 10 patients with extensively drug- resistant TB, hence signaling caution towards misuse of 2^nd^ line injectables [@pone.0055299-Chan1].

There was a distinct difference in the chances of finding XDR-TB in patients who hailed from a rural *vis a vis* urban background. MDR-TB patients in rural areas had higher chances of disease worsening to lead to XDR-TB; on the contrary, in patients who belonged to urban areas XDR-TB formed a smaller subset of MDR-TB patients. This was an incidental finding and may signal towards ignorance of rural patients towards available treatment options or possibly poor coverage of programmatic services in such areas ([Figure 3](#pone-0055299-g003){ref-type="fig"}).

Our data suggests that an inadequate initial drug regimen may be associated with the development of XDR, as we observed, 94.4% XDR-TB patients were previously treated for tuberculosis ([Table 2](#pone-0055299-t002){ref-type="table"}). These patients were already under medication for TB, though their compliance and dosage schedules, sources of medicine could not be ascertained. Disease worsening, accumulation of drug resistance, progression of MDR to XDR could all result from inadequate treatment.

High numbers of p-XDR-TB cases is a cause for great concern. OFX resistance seen in 7.4% of MDR strains and AMK/CAP resistance in 5.9% are only a single mutation away from converting to an XDR-TB strain. A recent study in South Africa raised the concern of those MDR-TB cases that were resistant to a single marker of XDR-TB (either OFX or KAN), as being at great risk of developing XDR-TB if not managed appropriately [@pone.0055299-Mlambo1]. Issues about poor/non-response to programmatic management of MDR-TB loom large due to such cases.

The XDR-TB patients were followed up and it was found that 4 (22.2%) expired during treatment, 1(5.5%) was treated successfully, 4 (22.2%) defaulted and 9 (50%) were not traceable. The treatment regimen being given to these patients is given in [Table 5](#pone-0055299-t005){ref-type="table"}.

Our study has a few limitations. Data on CXR, BCG vaccination and intake of injectable/fluoroquinolone were not available for all patients. Patients were not willing to give proper residential information; hence migrants could not be traced for follow up. Patients did not have proper previous medical records; hence it was difficult to explain the poor response or progress to drug resistant TB. The small number of XDR-TB (3.7%) cases was also a limitation. It is likely that a larger patient cohort would have shown a more significant association with various variables, including migrants, co-morbidity, socioeconomic status, age, sex, underlying diseases such as chronic obstructive pulmonary disease or abnormal liver function. Another limitation was that resistance to KAN was not checked in all the isolates and only for XDR-TB isolates. Maus *et al* have cautioned against the faulty practice of generalizing resistance to a class of drugs, e.g., cyclic peptides or aminoglycosides, based solely on the resistance to a single drug in the class [@pone.0055299-Maus1].

The percentage of MDR and XDR-TB patients that are detected depends on the study design, the sampling frame and the study population. There is a need to reevaluate and recalculate actual prevalence of XDR-TB from different population samples residing in various regions of India. Currently, the rapid diagnosis and treatment of persons with TB, particularly any form of drug- resistant TB, are high priority public health interventions. Effective control of drug resistant TB requires massive scaling-up of culture, DST capability and novel rapid assays to detect drug resistance [@pone.0055299-Jassal1]. DST is recommended universally for new and retreatment TB cases. Early treatment of MDR-TB with drugs reserved only for treating such patients would again contribute significantly to the control; though this would entail strict action to restrict the use of these drugs only for the program. A quick diagnosis of MDR and XDR-TB translates into greater likelihood of patient care and less spread of this potentially lethal strain thus benefiting the individual and the society. In addition, more exhaustive efforts should be made to manage drug resistant TB cases more effectively to improve treatment outcomes of all patients and hence minimize further development of TB resistant to all available drugs.
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